<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: early stage", fill: "#d4af37"},
{source: "5: early stage", target: "5: outlicensing", fill: "#d4af37"},
{source: "5: outlicensing", target: "5: proprietary drug", fill: "#d4af37"},
{source: "5: proprietary drug", target: "5: candidates", fill: "#d4af37"},
{source: "5: candidates", target: "5: drug discovery capabilities", fill: "#d4af37"},
{source: "5: early stage", target: "9: negative cash flows", fill: "#ff0"},
{source: "9: negative cash flows", target: "9: losses may continue", fill: "#ff0"},
{source: "9: losses may continue", target: "9: increase due", fill: "#ff0"},
{source: "9: increase due", target: "9: development particularly", fill: "#ff0"},
{source: "9: development particularly", target: "9: clinical development expansion", fill: "#ff0"},
{source: "9: clinical development expansion", target: "9: scientific capabilities", fill: "#ff0"},
{source: "9: scientific capabilities", target: "9: acquisitions", fill: "#ff0"},
{source: "9: acquisitions", target: "9: complementary technologies", fill: "#ff0"},
{source: "9: complementary technologies", target: "9: possible reductions", fill: "#ff0"},
{source: "9: possible reductions", target: "9: revenue from drug discovery collaborations", fill: "#ff0"},
{source: "9: negative cash flows", target: "13: collaboration", fill: "#c04000"},
{source: "13: collaboration", target: "13: agreements provide", fill: "#c04000"},
{source: "13: agreements provide", target: "13: royalties on product sales given", fill: "#c04000"},
{source: "13: royalties on product sales given", target: "13: candidates", fill: "#c04000"},
{source: "13: candidates", target: "13: been approved", fill: "#c04000"},
{source: "13: been approved", target: "13: commercial sale", fill: "#c04000"},
{source: "13: commercial sale", target: "13: at early stages", fill: "#c04000"},
{source: "13: at early stages", target: "13: development", fill: "#c04000"},
{source: "13: development", target: "13: drug development", fill: "#c04000"},
{source: "13: drug development", target: "13: several years", fill: "#c04000"},
{source: "13: collaboration", target: "15: incur significant additional", fill: "#cba135"},
{source: "15: incur significant additional", target: "15: clinical development capabilities", fill: "#cba135"},
{source: "15: clinical development capabilities", target: "15: commercialize ourselves", fill: "#cba135"},
{source: "15: commercialize ourselves", target: "15: commercialization", fill: "#cba135"},
{source: "15: commercialization", target: "15: revenue from such efforts", fill: "#cba135"},
{source: "15: revenue from such efforts", target: "15: several years", fill: "#cba135"},
{source: "15: incur significant additional", target: "16: been devoting", fill: "#556b2f"},
{source: "16: been devoting", target: "16: drug discovery", fill: "#556b2f"},
{source: "16: drug discovery", target: "16: proprietary drug programs", fill: "#556b2f"},
{source: "16: been devoting", target: "26: collaborators", fill: "#dcd0ff"},
{source: "26: collaborators", target: "26: discontinue", fill: "#dcd0ff"},
{source: "26: discontinue", target: "26: development", fill: "#dcd0ff"},
{source: "26: development", target: "26: drug candidate", fill: "#dcd0ff"},
{source: "26: drug candidate", target: "26: commercialize", fill: "#dcd0ff"},
{source: "26: collaborators", target: "37: drug candidates", fill: "#ae0c00"},
{source: "37: drug candidates", target: "37: drug discovery capabilities", fill: "#ae0c00"},
{source: "37: drug discovery capabilities", target: "37: rather than", fill: "#ae0c00"},
{source: "37: rather than", target: "37: them internally will depend on", fill: "#ae0c00"},
{source: "37: them internally will depend on", target: "37: discover competitive drug candidates targeting", fill: "#ae0c00"},
{source: "37: discover competitive drug candidates targeting", target: "37: market opportunities", fill: "#ae0c00"},
{source: "37: market opportunities", target: "37: drug discovery technologies", fill: "#ae0c00"},
{source: "37: drug discovery technologies", target: "37: identification", fill: "#ae0c00"},
{source: "37: identification", target: "37: high caliber scientists", fill: "#ae0c00"},
{source: "37: high caliber scientists", target: "37: timely high quality", fill: "#ae0c00"},
{source: "37: timely high quality", target: "37: manufacture", fill: "#ae0c00"},
{source: "37: manufacture", target: "37: chemical compounds", fill: "#ae0c00"},
{source: "37: chemical compounds", target: "37: purity levels", fill: "#ae0c00"},
{source: "37: purity levels", target: "37: collaborators", fill: "#ae0c00"},
{source: "37: drug candidates", target: "START_HERE", fill: "#ae0c00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Life and Health Insurance</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Capital Goods</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_development">Drug development</a></td>
      <td>Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery.  It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medication">Medication</a></td>
      <td>Meditation is a practice in which an individual uses a technique – such as mindfulness, or focusing the mind on a particular object, thought, or activity – to train attention and awareness, and achieve a mentally clear and emotionally calm and stable state.Meditation  is practiced in numerous religious traditions. The earliest records of meditation (dhyana) are found in the Upanishads of Hindu philosophy, and meditation plays a salient role in the contemplative repertoire of Buddhism and Hinduism.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/COVID-19_drug_development">COVID-19 drug development</a></td>
      <td>COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research (506 total candidates in April 2021), with 419 potential COVID-19 drugs in clinical trials, as of April 2021.As early as March 2020, the World Health Organization (WHO), European Medicines Agency (EMA), US Food and Drug Administration (FDA), and the Chinese government and drug manufacturers were coordinating with academic and industry researchers to speed development of vaccines, antiviral drugs, and post-infection therapies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization">Commercialization</a></td>
      <td>Commercialization or commercialisation is the process of introducing a new product or production method into commerce—making it available on the market. The term often connotes especially entry into the mass market (as opposed to entry into earlier niche markets), but it also includes a move from the laboratory into (even limited) commerce.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renewable_energy_commercialization">Renewable energy commercialization</a></td>
      <td>Renewable energy commercialization involves the deployment of three generations of renewable energy technologies dating back more than 100 years. First-generation technologies, which are already mature and economically competitive, include biomass, hydroelectricity, geothermal power and heat.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_design">Drug design</a></td>
      <td>Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_software">Collaborative software</a></td>
      <td>Collaborative software or groupware is application software designed to help people working on a common task to attain their goals. One of the earliest definitions of groupware is "intentional group processes plus software to support them".As regards available interaction, collaborative software may be divided into: real-time collaborative editing platforms that allow multiple users to engage in live, simultaneous and reversible editing of a single file (usually a document),  and version control (also known as revision control and source control) platforms, which allow separate users to make parallel edits to a file, while preserving every saved edit by every user as multiple files (that are variants of the original file).Collaborative software is a broad concept that overlaps considerably with computer-supported cooperative work (CSCW).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_metabolism">Drug metabolism</a></td>
      <td>Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism (from the Greek xenos "stranger"  and biotic "related to living beings") is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ARRAY BIOPHARMA INC      Item 1A Risk Factors       In addition to the other factors discussed elsewhere in this report and in     other reports we file with the SEC, the following factors could cause actual     results  or  events  to  differ <font color="blue">materially</font> from those contained in any     forward-looking statements made by us or on our behalf</td>
    </tr>
    <tr>
      <td>In addition, other     risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that we currently deem     <font color="blue">immaterial may impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If any of the following     risks or such other risks occur, it <font color="blue">could <font color="blue">adversely affect</font></font> our business,     operating results and <font color="blue">financial condition</font>, as well as cause the value of our     <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR BUSINESS       We have a history of losses and may not achieve or <font color="blue">sustain <font color="blue">profitability</font></font></td>
    </tr>
    <tr>
      <td>We are at an <font color="blue">early stage</font> of executing our business plan, and we have a     limited  history  of developing and out-licensing our <font color="blue"><font color="blue">proprietary</font> drug</font>     <font color="blue">candidates</font> and offering our <font color="blue"><font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">cap<font color="blue">abilities</font></font></font></td>
    </tr>
    <tr>
      <td>We have incurred     <font color="blue">significant</font> operating and net losses and <font color="blue">negative cash flows</font> from <font color="blue">operations</font>     since our inception</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we had an <font color="blue">accumulated deficit</font> of     dlra133dtta7 million</td>
    </tr>
    <tr>
      <td>We had net losses of dlra39dtta6 million, dlra23dtta2 million and     dlra26dtta0 million for the <font color="blue">fiscal years</font> ended June 30, 2006, 2005 and 2004,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">additional</font> losses and <font color="blue">negative cash flows</font>     in the future, and these <font color="blue">losses may continue</font> or <font color="blue">increase due</font> in part to     anticipated increases in expenses for research and <font color="blue">development</font>, particularly     clinical <font color="blue">development</font>, expansion of our clinical and <font color="blue">scientific <font color="blue">cap<font color="blue">abilities</font></font></font>,     <font color="blue"><font color="blue">acquisition</font>s</font> of <font color="blue">complementary <font color="blue">technologies</font></font> or in-licensed drug <font color="blue">candidates</font>     and <font color="blue">possible reductions</font> in <font color="blue"><font color="blue">revenue from</font> <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>We     may not be able to achieve or maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Moreover, if we do     achieve <font color="blue">profitability</font>, the level of any <font color="blue">profitability</font> cannot be predicted     and may vary <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td>Much of our <font color="blue">current revenue</font> is non-recurring in nature and unpredictable as     to timing and amount</td>
    </tr>
    <tr>
      <td>While several of our out-license and <font color="blue">collaboration</font>     <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> provide</font> for royalties on product sales, given that none of our     drug  <font color="blue">candidates</font> have <font color="blue">been approved</font> for <font color="blue">commercial sale</font>, that our drug     <font color="blue">candidates</font> are at <font color="blue">early stage</font>s of <font color="blue">development</font> and that drug <font color="blue">development</font>     entails a high risk of failure, we do not expect to receive any royalty     revenue for <font color="blue">several years</font>, if at all</td>
    </tr>
    <tr>
      <td>For the same reasons, we may never     realize much of the <font color="blue">milestone revenue provided</font> for in our out-license and     <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>We also expect to incur <font color="blue">significant</font> <font color="blue">additional</font>     costs to build our clinical <font color="blue">development</font> <font color="blue">cap<font color="blue">abilities</font></font> and to develop drugs we     select to <font color="blue"><font color="blue">commercialize</font> ourselves</font> or partner for later-stage co-<font color="blue">development</font>     and <font color="blue">commercialization</font>, and we may not realize <font color="blue"><font color="blue">revenue from</font> such efforts</font> for     <font color="blue">several years</font>, or at all</td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">been devoting</font> more resources     to <font color="blue">drug <font color="blue">discovery</font></font> and our <font color="blue"><font color="blue">proprietary</font> drug</font> programs</td>
    </tr>
    <tr>
      <td>As a result, we expect     that <font color="blue">revenue from</font> the sale of our research tools and services will continue     to  decline as a percentage of <font color="blue">total revenue</font> and that our research and     <font color="blue">development</font> and other <font color="blue">expenses will continue</font> to increase</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________         Our drug <font color="blue">candidates</font> are at <font color="blue">early stage</font>s of <font color="blue">development</font>, and we may not     <font color="blue">successfully</font> develop a <font color="blue">drug candidate</font> that becomes a <font color="blue">commercially viable</font>     drug</td>
    </tr>
    <tr>
      <td>The <font color="blue">drug <font color="blue">discovery</font></font> and <font color="blue">development</font> process is <font color="blue">highly uncertain</font>, and we have     not developed, and may never develop, a <font color="blue">drug candidate</font> that <font color="blue">ultimately leads</font>     to a <font color="blue">commercially viable</font> drug</td>
    </tr>
    <tr>
      <td>All of our drug <font color="blue">candidates</font> are in the early     stages of <font color="blue">development</font>, and we do not have any <font color="blue">drugs approved</font> for commercial     sale</td>
    </tr>
    <tr>
      <td>Before a drug product is approved by the FDA for commercial marketing,     it is tested for safety and <font color="blue"><font color="blue">effective</font>ness</font> in <font color="blue">clinical trial</font>s that can take     up to six years or longer</td>
    </tr>
    <tr>
      <td>At any time, a <font color="blue">clinical trial</font> can be placed on     “clinical hold”, or <font color="blue">temporarily</font> or <font color="blue">permanently</font> stopped for a variety of     reasons,  <font color="blue">principally</font> for <font color="blue">safety concerns</font></td>
    </tr>
    <tr>
      <td>Only one of our <font color="blue">candidates</font>,     ARRY-886,  is  in  a  Phase 2 <font color="blue">clinical trial</font>, a trial that our partner     <font color="blue">AstraZeneca </font>announced in June 2006</td>
    </tr>
    <tr>
      <td>ARRY-186 and two other <font color="blue">candidates</font>,     ARRY-543  and  ARRY-162, are currently in Phase 1 trials, and another,     ARRY-797,  is  expected  to enter a Phase 1 trial in the fall of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Candidates </font>that appear promising in pre-clinical or <font color="blue">clinical trial</font>s may fail     to <font color="blue">become marketed drugs</font> for a number of reasons, including:       ·                   the failure to achieve <font color="blue">clinical trial</font> results that     indicate a candidate is <font color="blue">effective</font> in treating a <font color="blue">specified condition</font> or     illness in humans;       ·                  the presence of harmful side effects;       ·                  the failure to obtain FDA or other <font color="blue"><font color="blue">regulatory</font> approval</font>;       ·                  the lack of <font color="blue">commercial viability</font> of the drug;       ·                  the failure to acquire, on reasonable terms, <font color="blue">intellectual</font>     <font color="blue"><font color="blue">property rights</font> necessary</font> for <font color="blue">commercialization</font>; and       ·                  the existence of <font color="blue">therapeutics</font> that are more <font color="blue">effective</font> or     economical to produce</td>
    </tr>
    <tr>
      <td>At  any  time,  we  or our <font color="blue">collaborators</font> may decide to <font color="blue">discontinue</font> the     <font color="blue">development</font> of a <font color="blue">drug candidate</font> or not to <font color="blue">commercialize</font> a candidate</td>
    </tr>
    <tr>
      <td>If we     terminate  a <font color="blue">preclinical program</font> in which we have invested <font color="blue">significant</font>     resources,  we will have <font color="blue">expended <font color="blue">resources on</font></font> a program that will not     provide a full return on our <font color="blue">investment</font> and missed the <font color="blue">opportunity</font> to have     allocated those resources to <font color="blue">potentially</font> more <font color="blue">productive uses</font></td>
    </tr>
    <tr>
      <td>Even if one     of  our  drug  <font color="blue">candidates</font>  receives <font color="blue"><font color="blue">regulatory</font> approval</font> for marketing,     physicians or <font color="blue">consumers may</font> not find that its <font color="blue"><font color="blue">effective</font>ness</font>, ease of use,     side effect profile, cost or other factors make it <font color="blue">effective</font> in treating     disease or more <font color="blue">beneficial than</font> or preferable to other drugs on the market</td>
    </tr>
    <tr>
      <td>Additionally,  <font color="blue">governments</font>  and  <font color="blue">health insurance</font> plans or maintenance     <font color="blue"><font color="blue">organizations</font> may choose</font> not to include the drug on their <font color="blue">formulary list</font> for     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>As a result, the drug may not be used or may be used only for     restricted <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">depends heavily on</font> the extent to which the <font color="blue">pharmaceutical</font> and     bio<font color="blue">technology</font> <font color="blue">industries</font> in-license drug <font color="blue">candidates</font> to fill their product     pipelines and <font color="blue">collaborate with</font> other companies for one or more aspects of     their <font color="blue">drug <font color="blue">discovery</font></font> process</td>
    </tr>
    <tr>
      <td>We  are highly <font color="blue">dependent</font> on <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font>     continuing to in-license drug <font color="blue">candidates</font> to fill their clinical <font color="blue">development</font>     pipelines and to <font color="blue">collaborate with</font> outside companies to obtain <font color="blue">drug <font color="blue">discovery</font></font>     expertise, and on their <font color="blue">willingness</font> to spend <font color="blue">significant</font> funds on research     and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">cap<font color="blue">abilities</font></font> include aspects of the <font color="blue">drug <font color="blue">discovery</font></font>     process that <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font> have <font color="blue">traditionally</font>     performed <font color="blue">internally</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">willingness</font> of these companies to in-license drug     <font color="blue">candidates</font>  and to expand or continue <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">collaboration</font>s to     enhance their research and <font color="blue">development</font> process is <font color="blue">based on several factors</font>     that are beyond our control</td>
    </tr>
    <tr>
      <td>These include their ability to hire and retain     qualified  <font color="blue">scientists</font>,  the <font color="blue">resources available</font> for <font color="blue">entering into drug</font>     <font color="blue">discovery</font> <font color="blue">collaboration</font>s and the <font color="blue">spending priorities among various types</font> of     research  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>In addition, our ability to convince these companies to in-license     our drug <font color="blue">candidates</font> or programs or to use our <font color="blue"><font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">cap<font color="blue">abilities</font></font></font>,     <font color="blue">rather than</font> develop them <font color="blue">internally</font>, will depend on many factors, including     our ability to:       ·                  discover competitive drug <font color="blue">candidates</font> targeting large     <font color="blue">market opportunities</font>;       14     ______________________________________________________________________         ·                  develop and implement <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">technologies</font> that     will result in the <font color="blue">identification</font> of higher-quality drug <font color="blue">candidates</font>;       ·                  attract and retain experienced, <font color="blue">high caliber</font> <font color="blue">scientists</font>;       ·                  achieve timely, <font color="blue">high quality</font> results at an acceptable     cost; and       ·                  design, create and <font color="blue">manufacture</font> our <font color="blue">chemical compounds</font> in     quantities,  at  <font color="blue">purity levels</font> and at costs that are acceptable to our     <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>The importance of these factors varies depending on the company and type of     <font color="blue"><font color="blue">discovery</font> program</font>, and although we believe we <font color="blue">currently address</font> many of     these factors, we may be unable to meet any or all of them in the future</td>
    </tr>
    <tr>
      <td>Even if we are able to address these factors, these companies may still     decide to perform these <font color="blue">activities</font> <font color="blue">internally</font>, acquire companies to fill     their <font color="blue">product pipelines</font> or retain other companies that <font color="blue">provide <font color="blue">drug research</font></font>     and <font color="blue">development</font> expertise similar to ours</td>
    </tr>
    <tr>
      <td>We may not be successful in entering into <font color="blue">additional</font> out-license <font color="blue"><font color="blue">agreement</font>s</font>     on favorable terms</td>
    </tr>
    <tr>
      <td>We are committing <font color="blue">significant</font> resources to create our own <font color="blue"><font color="blue">proprietary</font> drug</font>     <font color="blue">candidates</font> and to build a commercial-stage bio<font color="blue">pharmaceutical</font> company</td>
    </tr>
    <tr>
      <td>In     fiscal  2006,  we  increased our <font color="blue">investment</font> in <font color="blue"><font color="blue">proprietary</font> research</font> to     dlra33dtta4 million, compared to dlra22dtta9 million, dlra15dtta9 million for <font color="blue">fiscal years</font>     2005 and 2004, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">proprietary</font> drug</font> <font color="blue"><font color="blue">discovery</font> program</font>s are in     their <font color="blue">early stage</font> of <font color="blue">development</font> and are unproven</td>
    </tr>
    <tr>
      <td>To date, we have entered     into   three  out-licensing  <font color="blue"><font color="blue">agreement</font>s</font>  for  the  co-<font color="blue">development</font>  and     <font color="blue">commercialization</font> of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Although we have expended, and     continue to expend, <font color="blue">resources on</font> internal research and <font color="blue">development</font> for our     <font color="blue">proprietary</font>  programs,  we  may not be successful in creating valuable     <font color="blue">proprietary</font>  drug  <font color="blue">candidates</font> that <font color="blue">would enable us</font> to <font color="blue">enter <font color="blue">additional</font></font>     out-licensing  <font color="blue"><font color="blue">agreement</font>s</font>  with favorable terms that include up-front,     milestone, royalty and/or license payments</td>
    </tr>
    <tr>
      <td>In addition, we may undertake     and fund, solely at our expense, further <font color="blue">development</font>, <font color="blue">clinical trial</font>s,     <font color="blue">manufacturing</font> and marketing <font color="blue">activities</font> for a greater number of <font color="blue">proprietary</font>     <font color="blue">candidates</font> than we planned</td>
    </tr>
    <tr>
      <td>As a result, our <font color="blue">requirements</font> for capital, which     may not be available on favorable terms, could increase <font color="blue">significant</font>ly, or we     may be required to <font color="blue">substantially</font> reduce our <font color="blue">development</font> efforts, which would     delay, limit or prevent our ability to <font color="blue">commercialize</font> our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may not out-license our <font color="blue">proprietary</font> programs at the <font color="blue">most <font color="blue">appropriate</font></font> time     to maximize the <font color="blue">total value</font> or return of these programs to us</td>
    </tr>
    <tr>
      <td>A <font color="blue">critical aspect</font> of our business strategy is to out-license drug <font color="blue">candidates</font>     for late-stage co-<font color="blue">development</font> and <font color="blue">commercialization</font> to obtain the highest     possible value while also evaluating earlier out-<font color="blue">licensing opportunities</font> to     maximize our risk-adjusted return on our <font color="blue">investment</font> in <font color="blue"><font color="blue">proprietary</font> research</font></td>
    </tr>
    <tr>
      <td>Because the costs and risk of failure of bringing a drug to market are high,     the  value of out-licensing a <font color="blue">drug candidate</font> <font color="blue">generally</font> increases as it     <font color="blue">successfully</font> progresses through <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>Array may choose or be     forced to out-license a <font color="blue">drug candidate</font> or program on terms that require us     to <font color="blue">relinquish commercial</font> or <font color="blue">market rights</font> or at a point in the research and     <font color="blue">development</font> process that does not <font color="blue">provide as</font> great a value or <font color="blue">return than</font>     what might have been obtained if we had further developed the candidate or     program  <font color="blue">internally</font></td>
    </tr>
    <tr>
      <td>Likewise, we may decline, or be unable to obtain     favorable, early out-<font color="blue">licensing opportunities</font> in programs that do not result     in a <font color="blue">commercially viable</font> drug, which could leave the resulting <font color="blue">program with</font>     little or no value even though <font color="blue">significant</font> resources were invested in its     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">revenue from</font> our funded research <font color="blue">collaboration</font>s will decline     in  the  future as we focus more <font color="blue">resources on</font> our <font color="blue"><font color="blue">proprietary</font> research</font>     programs</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">revenue from</font> our funded research <font color="blue">collaboration</font>s to discover     drug <font color="blue">candidates</font> against targets our <font color="blue">collaborators</font> select will decline</td>
    </tr>
    <tr>
      <td>Historically,  revenue  from these <font color="blue">collaboration</font>s has <font color="blue">partially funded</font>     <font color="blue">development</font> of a fully capable <font color="blue">drug <font color="blue">discovery</font></font> platform for identifying and     developing <font color="blue">early stage</font> drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We believe the value of the drug     <font color="blue">candidates</font> Array has created for many of our <font color="blue">collaborators</font> under these     <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font> has exceeded the <font color="blue">economic reward provided</font> to us     under  the  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>One of our primary business strategies is to     transition  to a <font color="blue">partnering strategy</font> where, in addition to <font color="blue">potentially</font>     obtaining <font color="blue">higher milestone</font> and <font color="blue">royalty rates</font>, we would out-license later     stage <font color="blue">candidates</font> and retain <font color="blue">commercialization</font> or co-promotional rights in     parts of the world</td>
    </tr>
    <tr>
      <td>In order to transition to this approach, we expect to     make <font color="blue">significant</font> <font color="blue">investment</font>s in our own       15     ______________________________________________________________________         <font color="blue">drug <font color="blue">discovery</font></font> efforts to discover <font color="blue">additional</font> <font color="blue">candidates</font> for out-licensing     and that our <font color="blue">revenue will decline as</font> our historical <font color="blue">collaboration</font>s end</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> have substantial control and <font color="blue">discretion over</font> the timing     and the continued <font color="blue">development</font> and marketing of drug <font color="blue">candidates</font> we create for     them</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> have <font color="blue">significant</font> discretion in determining the efforts and     amount  of  resources  that  they  dedicate to our <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">collaborators</font> may determine not to proceed with clinical <font color="blue">development</font> or     <font color="blue">commercialization</font> of a particular <font color="blue">drug candidate</font> for a number of reasons     that are beyond our control, even under circumstances where we might have     <font color="blue">continued such</font> a program</td>
    </tr>
    <tr>
      <td>In addition, our ability to <font color="blue">generate milestone</font>     payments   and   royalties  from  our  <font color="blue">collaborators</font>  depends  on  our     <font color="blue">collaborators</font>’ <font color="blue">abilities</font> to establish the safety and efficacy of our drug     <font color="blue">candidates</font>, obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s and achieve <font color="blue">market <font color="blue">acceptance</font></font> of     products  developed  from  our  drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also depend on</font> our     <font color="blue">collaborators</font> to <font color="blue">manufacture</font> clinical scale quantities of some of our drug     <font color="blue">candidates</font> and <font color="blue">would depend on them</font> in the future for <font color="blue">commercial scale</font>     <font color="blue">manufacture</font>, <font color="blue">distribution</font> and <font color="blue">direct sales</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> may not be     successful in <font color="blue">manufacturing</font> our drug <font color="blue">candidates</font> on a <font color="blue">commercial scale</font> or in     <font color="blue">successfully</font> commercializing them</td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">additional</font> risks</font> in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">collaboration</font>s, including     the following:       ·                  our <font color="blue">collaborators</font> may develop and <font color="blue">commercialize</font>, either     alone  or  with  others,  products and services that are similar to or     <font color="blue">competitive with</font> the products that are the subject of the <font color="blue">collaboration</font> with     us;       ·                  our <font color="blue">collaborators</font> may underfund or not <font color="blue">commit sufficient</font>     resources to the testing, marketing, <font color="blue">distribution</font> or other <font color="blue">development</font> of     our drug <font color="blue">candidates</font>;       ·                  our <font color="blue">collaborators</font> may not properly maintain or defend our     <font color="blue"><font color="blue">intellectual</font> property</font> rights or they <font color="blue">may utilize</font> our <font color="blue">proprietary</font> information     in such a way as to <font color="blue">invite <font color="blue">litigation</font></font> that could jeopardize or <font color="blue">potentially</font>     invalidate our <font color="blue"><font color="blue">intellectual</font> property</font> or <font color="blue">proprietary</font> information or expose us     to <font color="blue">potential <font color="blue">liability</font></font>;       ·                  our <font color="blue">collaborators</font> may encounter conflicts of interest,     changes in business strategy or other business <font color="blue">issues which could adversely</font>     affect their <font color="blue">willingness</font> or ability to fulfill their <font color="blue">obligations</font> to us (for     example,  <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font> <font color="blue">historically</font> have     re-evaluated their <font color="blue">priorities following mergers</font> and <font color="blue">consolidation</font>s, which     have been common in <font color="blue">recent years</font> in these <font color="blue">industries</font>); and       ·                  <font color="blue">disputes may</font> arise <font color="blue">between us</font> and our <font color="blue">collaborators</font>     delaying or <font color="blue">terminating</font> the research, <font color="blue">development</font> or <font color="blue">commercialization</font> of     our drug <font color="blue">candidates</font>, resulting in <font color="blue">significant</font> <font color="blue">litigation</font> or <font color="blue">arbitration</font> that     could be time-consuming and expensive, or causing <font color="blue">collaborators</font> to act in     their own self-interest and not in the interest of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The  sale  and <font color="blue">manufacture</font> of drug <font color="blue">candidates</font> that we develop with our     <font color="blue">collaborators</font> or on our own may not receive <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">development</font>  and  <font color="blue">commercialization</font>  of  drug  <font color="blue">candidates</font> for our     <font color="blue">collaborators</font> and our own internal <font color="blue">drug <font color="blue">discovery</font></font> efforts are subject to     regulation</td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>products require lengthy and <font color="blue">costly testing</font> in     animals and humans and <font color="blue"><font color="blue">regulatory</font> approval</font> by governmental agencies prior to     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>It takes <font color="blue">several years</font> to complete testing, and failure     can occur at any stage of testing</td>
    </tr>
    <tr>
      <td>Results attained in <font color="blue">preclinical testing</font>     and  early  clinical  trials for any of our drug <font color="blue">candidates</font> may not be     <font color="blue">indicative</font> of results that are obtained in <font color="blue">later studies</font>, and <font color="blue">significant</font>     setbacks in advanced <font color="blue">clinical trial</font>s may arise, even after promising results     in <font color="blue">earlier studies</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials may</font> not <font color="blue">demonstrate sufficient safety</font>     and efficacy to obtain the requisite <font color="blue"><font color="blue">regulatory</font> approval</font>s or result in     <font color="blue">marketable products</font></td>
    </tr>
    <tr>
      <td>Based on results at any stage of testing, we or our     <font color="blue">collaborators</font>  may decide to repeat or redesign a trial or <font color="blue">discontinue</font>     <font color="blue">development</font> of a <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>Approval of a <font color="blue">drug candidate</font> as safe and <font color="blue">effective</font> for use in humans is     <font color="blue">never certain</font>, and <font color="blue"><font color="blue">regulatory</font> agencies may delay</font> or <font color="blue">deny approval</font> of drug     <font color="blue">candidates</font> for <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">agencies may also delay</font> or deny     <font color="blue">approval based on <font color="blue">additional</font> government regulation</font> or <font color="blue">administrative action</font>,     on changes in <font color="blue">regulatory</font> policy during the period of <font color="blue">clinical trial</font>s in     humans  and  <font color="blue">regulatory</font>  review  or on the <font color="blue">availability</font> of <font color="blue">alternative</font>     <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td><font color="blue">Similar  </font>delays and <font color="blue">denials may</font> be <font color="blue">encountered</font> in foreign     countries</td>
    </tr>
    <tr>
      <td>None of our <font color="blue">collaborators</font> have obtained <font color="blue">regulatory</font>       16     ______________________________________________________________________         approval to <font color="blue">manufacture</font> and sell drug <font color="blue">candidates</font> owned by us or identified     or developed under an <font color="blue">agreement</font> with us</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">collaborators</font> cannot     obtain this approval, we will not realize milestone or <font color="blue">royalty payments</font>     based on <font color="blue">commercialization</font> goals for these drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Even  if  our  drug  <font color="blue">candidates</font> obtain <font color="blue"><font color="blue">regulatory</font> approval</font>, we and our     <font color="blue">collaborators</font> will be subject to <font color="blue">ongoing government regulation</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> authorities approve any of our drug <font color="blue">candidates</font>, the     <font color="blue">manufacture</font>, marketing and sale of these <font color="blue">drugs will</font> be subject to strict and     <font color="blue">ongoing regulation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with this <font color="blue">regulation consumes</font> substantial     financial and <font color="blue"><font color="blue">management</font> resources</font> and <font color="blue">may expose us</font> and our <font color="blue">collaborators</font>     to the potential for other <font color="blue">adverse circumstances</font></td>
    </tr>
    <tr>
      <td>For example, approval for     a drug may be conditioned on costly post-marketing follow-up studies</td>
    </tr>
    <tr>
      <td><font color="blue">Based     </font>on these studies, if a <font color="blue">regulatory</font> authority does not believe that the drug     <font color="blue">demonstrates</font> a <font color="blue">clinical benefit</font> to patients, it <font color="blue">could limit</font> the <font color="blue"><font color="blue">indication</font>s</font>     for which a drug may be sold or revoke the drug’s marketing approval</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">identification</font> of certain side effects after a drug is on the     <font color="blue">market may</font> result in the <font color="blue">subsequent withdrawal</font> of approval, reformulation of     a drug, <font color="blue">additional</font> preclinical and <font color="blue">clinical trial</font>s and changes in labeling</td>
    </tr>
    <tr>
      <td>Any of these events could delay or prevent us from <font color="blue">generating</font> <font color="blue">revenue from</font>     the <font color="blue">commercialization</font> of these drugs and cause us to incur <font color="blue">significant</font>     <font color="blue">additional</font> costs</td>
    </tr>
    <tr>
      <td>In addition, the marketing of these <font color="blue">drugs by us</font> or our <font color="blue">collaborators</font> will be     <font color="blue">regulated by federal</font> and state <font color="blue">laws pertaining</font> to <font color="blue">health care</font> “fraud and     abuse,” such as the federal anti-kickback law prohibiting bribes, kickbacks     or other <font color="blue">remuneration</font> for the order or <font color="blue">recommendation</font> of items or services     <font color="blue">reimbursed by federal <font color="blue">health care</font> programs</font></td>
    </tr>
    <tr>
      <td>Many states have similar laws     applicable  to  items  or  <font color="blue">services reimbursed by commercial insurers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of fraud and abuse laws can result in fines and/or <font color="blue">imprisonment</font></td>
    </tr>
    <tr>
      <td>If our drug <font color="blue">candidates</font> do not gain <font color="blue">market <font color="blue">acceptance</font></font>, we may be unable to     generate <font color="blue">significant</font> revenue</td>
    </tr>
    <tr>
      <td>Even  if  our  drug  <font color="blue">candidates</font> are approved for sale, they may not be     successful  in  the  marketplace</td>
    </tr>
    <tr>
      <td>Market <font color="blue">acceptance</font> of any of our drug     <font color="blue">candidates</font> will depend on a number of factors including:       ·                  <font color="blue">demonstration</font> of clinical <font color="blue"><font color="blue">effective</font>ness</font> and safety;       ·                  the <font color="blue">potential advantages</font> of our drug <font color="blue">candidates</font> over     <font color="blue">alternative</font> <font color="blue">treatments</font>;       ·                  the ability to offer our drug <font color="blue">candidates</font> for sale at     <font color="blue">competitive prices</font>;       ·                  the <font color="blue">availability</font> of adequate third-party <font color="blue">reimbursement</font>;     and       ·                  the <font color="blue"><font color="blue">effective</font>ness</font> of marketing and <font color="blue"><font color="blue">distribution</font> methods</font>     for the products</td>
    </tr>
    <tr>
      <td>If our drug <font color="blue">candidates</font> do not gain <font color="blue">market <font color="blue">acceptance</font></font> among physicians,     patients  and others in the <font color="blue">medical community</font>, our ability to generate     <font color="blue">meaningful revenues from</font> our drug <font color="blue">candidates</font> would be limited</td>
    </tr>
    <tr>
      <td>If  we need but are unable to obtain <font color="blue">additional</font> funding to support our     <font color="blue">operations</font>, we could be unable to <font color="blue">successfully</font> execute our operating plan or     be forced to reduce our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">historically</font>  funded our <font color="blue">operations</font> through <font color="blue">revenue from</font> our     <font color="blue">collaboration</font>s and the issuance of <font color="blue">equity securities</font></td>
    </tr>
    <tr>
      <td>We used dlra24dtta3 million     in our operating <font color="blue">activities</font> in fiscal 2006 while we used dlra17dtta2 million in     our operating <font color="blue">activities</font> in fiscal 2005</td>
    </tr>
    <tr>
      <td>Although we anticipate that we will     use more cash in our operating <font color="blue">activities</font> in <font color="blue">future periods</font>, we believe that     our  existing  cash,  cash  <font color="blue">equivalents</font>  and <font color="blue">marketable securities</font> and     anticipated cash flow from existing out-license and <font color="blue">collaboration</font> <font color="blue"><font color="blue">agreement</font>s</font>     will be sufficient to support our current operating plan for at least the     next 12 months</td>
    </tr>
    <tr>
      <td>However, our current operating plan and <font color="blue">assumptions</font> could     change as a result of many factors, and we could require <font color="blue">additional</font> funding     <font color="blue">sooner than</font> anticipated</td>
    </tr>
    <tr>
      <td>To  the  extent  that the cash from our future operating <font color="blue">activities</font> is     insufficient to meet our future capital <font color="blue">requirements</font>, we will have to raise     <font color="blue">additional</font> funds to continue our <font color="blue"><font color="blue">proprietary</font> research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We     may not be able to <font color="blue">raise funds on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>To the extent     that we raise <font color="blue">additional</font> capital through the sale       17     ______________________________________________________________________         of equity or convertible debt securities, the issuance of those securities     would result in dilution to our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We have a credit <font color="blue">facility</font>     providing for a dlra10 million term loan, and a dlra5 million equipment line of     which a total of dlra14dtta1 million was advanced to us as of June 30, 2006</td>
    </tr>
    <tr>
      <td>In     addition we have a dlra6dtta8 million revolving line of credit to <font color="blue">support standby</font>     letters of credit</td>
    </tr>
    <tr>
      <td>A portion of our <font color="blue">cash flow will</font> be dedicated to the     payment of principal and interest on such indebtedness, which could render     us more vulnerable to <font color="blue">competitive pressures</font> and <font color="blue">economic downturns</font> and     imposes some <font color="blue">restrictions on</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we are unable to obtain     <font color="blue">additional</font> funds when needed, we may be required to curtail <font color="blue">operations</font>     <font color="blue">significant</font>ly or to obtain <font color="blue">funds through</font> other <font color="blue">arrangements on unattractive</font>     terms, which could prevent us from <font color="blue">successfully</font> executing our operating     plan</td>
    </tr>
    <tr>
      <td>We have limited clinical <font color="blue">development</font> and <font color="blue">commercialization</font> experience</td>
    </tr>
    <tr>
      <td>One of our business strategies is to develop select drug <font color="blue">candidates</font> through     later stage <font color="blue">clinical trial</font>s before out-licensing them to a <font color="blue">pharmaceutical</font> or     <font color="blue">bio<font color="blue">technology</font> partner</font> for further clinical <font color="blue">development</font> and <font color="blue">commercialization</font>     and to <font color="blue">commercialize</font> select drug <font color="blue">candidates</font> ourselves</td>
    </tr>
    <tr>
      <td>To date, we have     <font color="blue">filed three</font> IND <font color="blue"><font color="blue">application</font>s</font> and <font color="blue">initiated three</font> Phase 1 <font color="blue">clinical trial</font>s,     and  we have not yet conducted a Phase 2 or later stage <font color="blue">clinical trial</font>     ourselves, nor have we <font color="blue">commercialize</font>d a drug</td>
    </tr>
    <tr>
      <td>We have limited experience     conducting <font color="blue">clinical trial</font>s and obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s, and we may     not be successful in some or all of these <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We have no experience     as a company in the sales, marketing and <font color="blue">distribution</font> of <font color="blue">pharmaceutical</font>     products and do not currently have a sales and <font color="blue">marketing organization</font></td>
    </tr>
    <tr>
      <td>We     expect to expend <font color="blue">significant</font> amounts to recruit and retain <font color="blue">high quality</font>     personnel with clinical <font color="blue">development</font> experience</td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font><font color="blue">commercialization</font>     <font color="blue">cap<font color="blue">abilities</font></font> would be expensive and time-consuming, could delay any product     launch, and we may never be able to develop this <font color="blue">capacity</font></td>
    </tr>
    <tr>
      <td>To the extent we     are unable or determine not to acquire these resources <font color="blue">internally</font>, we may be     forced to rely on third-party clinical <font color="blue">investigators</font>, clinical research or     <font color="blue">marketing organization</font>s, which could subject us to costs and to delays that     are outside our control</td>
    </tr>
    <tr>
      <td>If we are unable to establish adequate <font color="blue">cap<font color="blue">abilities</font></font>     <font color="blue">in<font color="blue">dependent</font>ly</font> or <font color="blue">with others</font>, we may be unable to <font color="blue">generate product revenues</font>     for certain <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">cap<font color="blue">abilities</font></font> may not produce <font color="blue">viable drug</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into several research</font> and <font color="blue">development</font> <font color="blue">collaboration</font>s under     which we provide <font color="blue">drug <font color="blue">discovery</font></font> services to identify drug <font color="blue">candidates</font> for our     <font color="blue">collaborators</font> using the <font color="blue">Array Discovery Platform</font></td>
    </tr>
    <tr>
      <td>We also seek to identify     and develop drug <font color="blue">candidates</font> for our <font color="blue">proprietary</font> programs</td>
    </tr>
    <tr>
      <td>It is uncertain     whether we will be able to provide <font color="blue">drug <font color="blue">discovery</font></font> more <font color="blue">efficiently</font> or create     high  quality  drug  <font color="blue">candidates</font>  that  are  suitable  for  our  or our     <font color="blue">collaborators</font>’ purposes, which may result in delayed or lost revenue, loss     of  <font color="blue">collaborators</font> or failure to expand our <font color="blue">existing relationships</font></td>
    </tr>
    <tr>
      <td>Our     ability to create <font color="blue">viable drug</font> <font color="blue">candidates</font> for ourselves and our <font color="blue">collaborators</font>     depends  on  many factors, including the <font color="blue">implementation</font> of <font color="blue">appropriate</font>     <font color="blue">technologies</font>,  the  <font color="blue">development</font>  of  <font color="blue">effective</font> new research tools, the     <font color="blue">complexity</font> of the <font color="blue">chemistry</font> and biology, the lack of <font color="blue">predictability</font> in the     <font color="blue">scientific process</font> and the performance and decision-making <font color="blue">cap<font color="blue">abilities</font></font> of     our <font color="blue">scientists</font></td>
    </tr>
    <tr>
      <td>Our information-driven <font color="blue">technology</font> platform, which we believe     allows  our  <font color="blue">scientists</font>  to  make better <font color="blue">decisions</font>, may not enable our     <font color="blue">scientists</font> to make correct <font color="blue">decisions</font> or develop <font color="blue">viable drug</font> <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If  our  drug  <font color="blue">discovery</font>  and  <font color="blue">development</font> programs do not progress as     anticipated, our revenue and <font color="blue">stock price could</font> be <font color="blue">negatively impacted</font></td>
    </tr>
    <tr>
      <td>We estimate the timing of a variety of preclinical, clinical, <font color="blue">regulatory</font> and     other <font color="blue">milestones</font> for planning purposes, including when a <font color="blue">drug candidate</font> is     expected to enter <font color="blue">clinical trial</font>s, when a <font color="blue">clinical trial</font> will be completed     or when an <font color="blue">application</font> for <font color="blue"><font color="blue">regulatory</font> approval</font> will be filed</td>
    </tr>
    <tr>
      <td>We base our estimates on facts that     are <font color="blue">currently known</font> to us and on a variety of <font color="blue">assumptions</font>, many of which are     beyond our control</td>
    </tr>
    <tr>
      <td>Delays may be caused by <font color="blue">regulatory</font> or <font color="blue">patent issues</font>,     interim or final results of on-going <font color="blue">clinical trial</font>s, scheduling conflicts     <font color="blue">with participating clinics</font> and the <font color="blue">availability</font> of patients who meet the     criteria for, and the rate of <font color="blue">patient enrollment</font> in, <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>If we     or our <font color="blue">collaborators</font> do not achieve <font color="blue">milestones</font> when anticipated, we may not     achieve our planned revenue, and our <font color="blue">stock price could</font> decline</td>
    </tr>
    <tr>
      <td>We may not realize anticipated benefits from future <font color="blue"><font color="blue">acquisition</font>s</font></td>
    </tr>
    <tr>
      <td>As  part  of  our business strategy, we may acquire, invest in or form     strategic <font color="blue">partnership</font>s with businesses with complementary products, services     and/or  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>and strategic <font color="blue">partnership</font>s involve     numerous risks, including, but not limited to:       18     ______________________________________________________________________         ·                  <font color="blue"><font color="blue">difficult</font>ies</font> and increased costs in <font color="blue"><font color="blue">connection</font> with</font>     <font color="blue">integration</font> of the personnel, <font color="blue">operations</font>, <font color="blue">technologies</font> and products of     acquired companies;       ·                   diversion  of  <font color="blue">management</font>’s  attention  from other     <font color="blue">operational matters</font>;       ·                  the <font color="blue">potential loss</font> of <font color="blue">key employees</font>;       ·                  the <font color="blue">potential loss</font> of key <font color="blue">collaborators</font>;       ·                  lack of synergy, or the <font color="blue">inability</font> to realize expected     synergies, resulting from the <font color="blue">acquisition</font> or <font color="blue">partnership</font>; and       ·                  <font color="blue">impairment</font> of acquired <font color="blue">intangible assets as</font> a result of     <font color="blue">technological</font>  <font color="blue">advancements</font>  or worse-than-expected performance of the     acquired company or the <font color="blue">partnered assets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Mergers  </font>and <font color="blue"><font color="blue">acquisition</font>s</font> are inherently risky and involve <font color="blue">significant</font>     <font color="blue">investment</font>s in time and resources to <font color="blue">effective</font>ly manage these risks and     integrate an acquired business</td>
    </tr>
    <tr>
      <td>Even with <font color="blue">investment</font>s in time and resources,     an  <font color="blue">acquisition</font> or strategic <font color="blue">partnership</font> may not produce the revenues,     earnings or business synergies we anticipate</td>
    </tr>
    <tr>
      <td>An <font color="blue">acquisition</font> that fails to     meet our <font color="blue">expectations</font> could <font color="blue">materially</font> and <font color="blue">adversely affect</font> our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Because we rely on a small number of <font color="blue">collaborators</font> for a <font color="blue">significant</font> portion     of our revenue, if one or more of our major <font color="blue">collaborators</font> terminates or     reduces the scope of their <font color="blue">agreement</font> with us, our revenue may <font color="blue">significant</font>ly     decrease</td>
    </tr>
    <tr>
      <td>A <font color="blue">relatively</font> small number of <font color="blue">collaborators</font> account for a <font color="blue">significant</font> portion     of our revenue</td>
    </tr>
    <tr>
      <td>Genentech, InterMune and <font color="blue">AstraZeneca </font>accounted for 35prca, 24prca     and 16prca, <font color="blue">respectively</font> of our <font color="blue">total revenue</font> in fiscal 2006</td>
    </tr>
    <tr>
      <td>In fiscal 2005     the same <font color="blue">collaborators</font> accounted for 28prca, 10prca and 27prca <font color="blue">respectively</font> of our     total  revenue</td>
    </tr>
    <tr>
      <td>We  expect  that  revenue  from  a limited number of     <font color="blue">collaborators</font>, including Genentech, InterMune and Ono <font color="blue">will account</font> for a     large  portion  of  our  revenue  in  <font color="blue">future quarters</font></td>
    </tr>
    <tr>
      <td>In general, our     <font color="blue">collaborators</font> may terminate their <font color="blue">contracts with us</font> upon 90 to 120 days’     notice for a number of reasons</td>
    </tr>
    <tr>
      <td>In addition, some of our major <font color="blue">collaborators</font>     can determine the amount of products delivered and research or <font color="blue">development</font>     performed under these <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>As a result, if any one of our major     <font color="blue">collaborators</font>  cancels,  declines to renew or reduces the scope of its     contract with us, our revenue may <font color="blue">significant</font>ly decrease</td>
    </tr>
    <tr>
      <td>We may not be able to recruit and retain the experienced <font color="blue">scientists</font> and     <font color="blue">management</font> we need to compete in the <font color="blue">drug research</font> and <font color="blue">development</font> industry</td>
    </tr>
    <tr>
      <td>We have 276 employees as of June 30, 2006, and our <font color="blue">future success depends</font>     upon our ability to attract, retain and motivate highly skilled <font color="blue">scientists</font>     and <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>Our ability to achieve our business strategies, including     progressing   drug  <font color="blue">candidates</font>  through  later  stage  <font color="blue">development</font>  or     <font color="blue">commercialization</font>, <font color="blue">attracting new</font> <font color="blue">collaborators</font> and retaining, renewing and     expanding existing <font color="blue">collaboration</font>s, depends on our ability to hire and retain     high  caliber <font color="blue">scientists</font> and other <font color="blue">qualified experts</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font>     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font>, contract research companies and     academic  and <font color="blue"><font color="blue">research institution</font>s</font> to <font color="blue">recruit personnel</font></td>
    </tr>
    <tr>
      <td>We may incur     <font color="blue">greater costs than</font> anticipated, or may not be successful, in <font color="blue">attracting new</font>     <font color="blue">scientists</font>  or  <font color="blue">management</font>  or in retaining or motivating our existing     personnel</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future success also depends on</font> the <font color="blue">personal efforts</font> and <font color="blue">abilities</font> of the     <font color="blue">principal members</font> of our senior <font color="blue">management</font> and <font color="blue">scientific staff</font> to provide     strategic direction, manage our <font color="blue">operations</font> and maintain a cohesive and     <font color="blue">stable environment</font></td>
    </tr>
    <tr>
      <td>In particular, we rely on the services of Robert E     Conway, our Chief Executive Officer; Dr</td>
    </tr>
    <tr>
      <td>Kevin Koch, our President and Chief     Scientific Officer; Dr</td>
    </tr>
    <tr>
      <td>David L Snitman, our <font color="blue">Chief Operating Officer </font>and     Vice President, Business Development; R Michael Carruthers, our Chief     Financial  Officer;  and John R Moore, our Vice President and General     Counsel</td>
    </tr>
    <tr>
      <td>We have employment <font color="blue"><font color="blue">agreement</font>s</font> with all of the above personnel that     are terminable upon 30 days’ prior notice</td>
    </tr>
    <tr>
      <td>In addition, we believe that     <font color="blue">successfully</font> building our clinical <font color="blue">development</font> <font color="blue">cap<font color="blue">abilities</font></font> depends to a     great extent on our ability to recruit and retain a <font color="blue">high caliber</font> Chief     Medical Officer</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot attract</font> and retain a <font color="blue">Chief Medical Officer </font>or     other  qualified  <font color="blue">scientists</font>  and  <font color="blue">management</font>,  we  may not be able to     <font color="blue">successfully</font> execute our operating plan</td>
    </tr>
    <tr>
      <td>Our cGMP and <font color="blue">pharmacology <font color="blue">facilities</font></font> and <font color="blue">practices may fail</font> to <font color="blue">comply with</font>     <font color="blue">government <font color="blue">regulations</font></font></td>
    </tr>
    <tr>
      <td>All <font color="blue">facilities</font> and <font color="blue">manufacturing</font> processes used in the production of Active     <font color="blue">Pharmaceutical </font>Ingredients for clinical use <font color="blue">in the <font color="blue">United States </font></font>must be     operated in <font color="blue">conformity with current</font> <font color="blue">Good Manufacturing Practices       </font>19     ______________________________________________________________________         (cGMP), as established by the FDA We operate a clinical-scale <font color="blue">manufacturing</font>     <font color="blue">facility</font> that we believe conforms with cGMP <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">facility</font> and     our <font color="blue">cGMP practices</font> are subject to periodic <font color="blue">regulatory</font> inspections to ensure     compliance with cGMP <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>In addition, we could be required to     <font color="blue">comply with</font> specific <font color="blue">requirements</font> of our <font color="blue">collaborators</font>, which may exceed FDA     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Failure on our part to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> and     specific <font color="blue">requirements</font> of our <font color="blue">collaborators</font> could result in the <font color="blue">termination</font>     of  <font color="blue">ongoing research</font> or the <font color="blue">disqualification</font> of data for submission to     <font color="blue">regulatory</font> authorities</td>
    </tr>
    <tr>
      <td>Material violations of cGMP <font color="blue">requirements</font> could     result in <font color="blue">regulatory</font> sanctions and, in severe cases, could result in a     mandated closing of our cGMP <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>In addition, our pharmacology <font color="blue">facility</font> may be subject to the <font color="blue"><font color="blue">United States </font>    </font>Department of Agriculture (USDA) <font color="blue">regulations</font> for <font color="blue">certain animal</font> species</td>
    </tr>
    <tr>
      <td>Failure on our part to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> and specific     <font color="blue">requirements</font> of our <font color="blue">collaborators</font> could result in the <font color="blue">termination</font> of ongoing     <font color="blue">pharmacology research</font></td>
    </tr>
    <tr>
      <td>Material violations of USDA <font color="blue">requirements</font> could result     in <font color="blue">additional</font> <font color="blue">regulatory</font> sanctions and, in severe cases, could result in a     mandated closing of our pharmacology <font color="blue">facility</font> for certain species</td>
    </tr>
    <tr>
      <td>Our <font color="blue">development</font>, testing and <font color="blue">manufacture</font> of drug <font color="blue">candidates</font> <font color="blue">may expose us</font> to     <font color="blue">product <font color="blue">liability</font> lawsuits</font></td>
    </tr>
    <tr>
      <td>We develop, test and <font color="blue">manufacture</font> drug <font color="blue">candidates</font> that are <font color="blue">generally</font> intended     for use in humans</td>
    </tr>
    <tr>
      <td>Our <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">activities</font>, including <font color="blue">clinical trial</font>s     we or our <font color="blue">collaborators</font> conduct, that result in the future <font color="blue">manufacture</font> and     sale of <font color="blue">drugs by us</font> or our <font color="blue">collaborators</font> expose us to the risk of <font color="blue">liability</font>     for  personal  injury or death to <font color="blue">persons using</font> these drugs</td>
    </tr>
    <tr>
      <td>We may be     required to pay substantial damages or <font color="blue">incur legal costs</font> in <font color="blue"><font color="blue">connection</font> with</font>     defending any of these product <font color="blue">liability</font> claims, or we may not receive     <font color="blue">revenue from</font> expected royalty or <font color="blue">milestone payments</font> if the <font color="blue">commercialization</font>     of a drug is limited or <font color="blue">ceases as</font> a result of such claims</td>
    </tr>
    <tr>
      <td>We have product     <font color="blue">liability</font> insurance that <font color="blue">contains customary exclusions</font> and <font color="blue">provides coverage</font>     up to dlra3dtta0 million per occurrence and in the aggregate, which we believe is     customary in our industry for our current <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>However, our product     <font color="blue">liability</font> insurance does not <font color="blue">cover every</font> type of product <font color="blue">liability</font> claim     that we may face or loss we may incur, and may not <font color="blue">adequately <font color="blue">compensate us</font></font>     for the <font color="blue">entire amount</font> of covered claims or losses or for the harm to our     business reputation</td>
    </tr>
    <tr>
      <td>We may be unable to acquire or maintain <font color="blue">additional</font> or     maintain our <font color="blue">current insurance policies at</font> acceptable costs or at all</td>
    </tr>
    <tr>
      <td>If our use of chemical and <font color="blue"><font color="blue">hazardous</font> materials violates applicable laws</font> or     <font color="blue">regulations</font> or causes <font color="blue">personal injury</font> we may be liable for damages</td>
    </tr>
    <tr>
      <td>Our <font color="blue">drug <font color="blue">discovery</font></font> <font color="blue">activities</font>, including the analysis and synthesis of     <font color="blue">chemical compounds</font>, involve the <font color="blue">controlled use</font> of <font color="blue">chemicals</font>, including     flammable, combustible, toxic and <font color="blue">radioactive materials</font> that are <font color="blue">potentially</font>     <font color="blue">hazardous</font></td>
    </tr>
    <tr>
      <td>Our use, storage, handling and disposal of these materials is     subject to federal, state and local laws and <font color="blue">regulations</font>, including the     Resource Conservation and Recovery Act, the Occupational Safety and Health     Act and local fire codes, and <font color="blue">regulations</font> promulgated by <font color="blue">the Department </font>of     Transportation, the Drug Enforcement Agency, <font color="blue">the Department </font>of Energy, the     Colorado Department of Public Health and Environment, and the Colorado     Department of Human Services, Alcohol and Drug Abuse Division</td>
    </tr>
    <tr>
      <td>We may incur     <font color="blue">significant</font> costs to <font color="blue">comply with</font> these laws and <font color="blue">regulations</font> in the future</td>
    </tr>
    <tr>
      <td>In  addition,  we  cannot  <font color="blue">completely eliminate</font> the risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials, which could result in material     unanticipated expenses, such as substantial fines or penalties, remediation     costs or damages, or the loss of a permit or other <font color="blue">authorization</font> to operate     or engage in our business</td>
    </tr>
    <tr>
      <td>Those <font color="blue">expenses could exceed</font> our net worth and     limit our ability to raise <font color="blue">additional</font> capital</td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> could be <font color="blue">interrupted by damage</font> to our <font color="blue">specialized laboratory</font>     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">operations</font>  are  <font color="blue">dependent</font>  upon  the <font color="blue">continued use</font> of our highly     <font color="blue">specialized laboratories</font> and equipment in Boulder and Longmont, Colorado</td>
    </tr>
    <tr>
      <td><font color="blue">Catastrophic  </font>events,  including fires or explosions, could damage our     laboratories, equipment, scientific data, work in progress or <font color="blue">inventories</font> of     <font color="blue">chemical compounds</font> and may <font color="blue">materially</font> interrupt our business</td>
    </tr>
    <tr>
      <td>We employ     <font color="blue">safety precautions</font> in our laboratory <font color="blue">activities</font> in order to reduce the     likelihood of the occurrence of these catastrophic events; however, we     <font color="blue">cannot eliminate</font> the chance that such an <font color="blue">event will</font> occur</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font>     of  <font color="blue">laboratory space</font> in these locations is limited, and rebuilding our     <font color="blue">facilities</font> could be time consuming and result in substantial delays in     fulfilling our <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>We maintain business     <font color="blue">interruption insurance</font> in the amount of dlra18dtta0 million to <font color="blue">cover continuing</font>     expenses  and  lost  revenue caused <font color="blue">by such occurrences</font></td>
    </tr>
    <tr>
      <td>However, this     insurance does not <font color="blue">compensate us</font> for the loss of <font color="blue">opportunity</font> and potential     harm to <font color="blue">customer relations</font> that our <font color="blue">inability</font> to meet our <font color="blue">collaborators</font>’     needs in a <font color="blue">timely manner could</font> create</td>
    </tr>
    <tr>
      <td>20     ______________________________________________________________________                             RISKS RELATED TO OUR INDUSTRY       The <font color="blue">concentration</font> of the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> industry</font> and any     further  <font color="blue">consolidation</font>  could  reduce  the  number  of  our  potential     <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>There are a limited number of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font>,     and these <font color="blue">companies represent</font> a <font color="blue">significant</font> portion of the market for our     <font color="blue">cap<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>The number of our potential <font color="blue">collaborators</font> could decline even     further through <font color="blue">consolidation</font> among these companies</td>
    </tr>
    <tr>
      <td>If the number of our     potential <font color="blue">collaborators</font> declines even further, they may be able to negotiate     greater rights to the <font color="blue"><font color="blue">intellectual</font> property</font> they license from us, price     <font color="blue">discounts</font> or other terms that are unfavorable to us</td>
    </tr>
    <tr>
      <td><font color="blue">Capital  </font><font color="blue">market <font color="blue">conditions</font> may reduce</font> our bio<font color="blue">technology</font> <font color="blue">collaborators</font>’     ability to <font color="blue">fund research</font></td>
    </tr>
    <tr>
      <td>Traditionally, many unprofitable <font color="blue">bio<font color="blue">technology</font> companies</font> have funded their     research and <font color="blue">development</font> <font color="blue">expenditures</font> through raising capital in the equity     markets</td>
    </tr>
    <tr>
      <td><font color="blue">Declines  </font>and  <font color="blue">uncertainties</font>  in these markets have severely     restricted raising new capital at times in the past and have affected these     companies’ ability to continue to expand or <font color="blue">fund existing research</font> and     <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>If our current or future bio<font color="blue">technology</font> <font color="blue">collaborators</font>     are unable to <font color="blue">raise sufficient capital</font> to <font color="blue">fund research</font> and <font color="blue">development</font>     <font color="blue">expenditures</font>, we may not be able to expand or maintain <font color="blue">current revenue</font></td>
    </tr>
    <tr>
      <td>Health <font color="blue">care reform</font> and cost control <font color="blue">initiatives</font> by third-party payors could     reduce the prices that can be charged for drugs, which <font color="blue">could limit</font> the     <font color="blue">commercial success</font> of our drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our drug <font color="blue">candidates</font> will depend <font color="blue">significant</font>ly on     the <font color="blue">availability</font> of <font color="blue">reimbursement</font> to the <font color="blue">patient from <font color="blue">third party</font> payors</font>,     such as <font color="blue">governments</font> and <font color="blue">private insurance</font> plans</td>
    </tr>
    <tr>
      <td>In the United States, the     Medicare Prescription Drug Improvement and Modernization Act of 2003 added a     <font color="blue">prescription</font>  drug  benefit  <font color="blue">to Medicare </font>beginning in 2006 and added a     <font color="blue">voluntary drug discount card program</font> for Medicare <font color="blue">beneficiaries otherwise</font>     without <font color="blue">prescription</font> drug coverage</td>
    </tr>
    <tr>
      <td>However, <font color="blue">future legislation may limit</font>     the  prices that can be charged for drugs we develop and may limit our     commercial <font color="blue">opportunity</font> and reduce any <font color="blue">associated revenue</font> and profits</td>
    </tr>
    <tr>
      <td>For     example, federal laws require drug <font color="blue">manufacture</font>rs to <font color="blue">pay specified rebates</font>     for  medicines  reimbursed  by  <font color="blue">Medicaid  </font>and to provide <font color="blue">discounts</font> for     out-patient medicines purchased by certain public health service entities     and “<font color="blue">disproportionate</font> share” hospitals and for <font color="blue">purchases by</font> some federal     <font color="blue">governmental departments such as</font> <font color="blue">the Department </font>of Veterans Affairs and the     <font color="blue">Department of Defense</font></td>
    </tr>
    <tr>
      <td>In some countries other than the United States,     <font color="blue">reimbursement</font>, pricing and <font color="blue">profitability</font> of <font color="blue">prescription</font> <font color="blue">pharmaceutical</font>s and     bio<font color="blue">pharmaceutical</font>s  are subject to <font color="blue">government control</font></td>
    </tr>
    <tr>
      <td>Also, we expect     <font color="blue">managed care will continue</font> to <font color="blue">put pressure on</font> the pricing of <font color="blue">pharmaceutical</font>     and bio<font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">control <font color="blue">initiatives</font> could decrease</font> the     price that we, or any potential <font color="blue">collaborators</font> receive for any of our future     products, which <font color="blue">could <font color="blue">adversely affect</font></font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">initiatives</font>     may also have the effect of reducing the resources that <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font> companies</font> can devote to in-licensing drug <font color="blue">candidates</font> and the     research and <font color="blue">development</font> of new drugs, <font color="blue">which could reduce</font> our resulting     revenue</td>
    </tr>
    <tr>
      <td>We or our <font color="blue">collaborators</font> may not obtain favorable <font color="blue">reimbursement</font> rates for our     drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Third  party  payors,  <font color="blue">such as government</font> and <font color="blue">private insurance</font> plans,     <font color="blue">frequently</font> require companies to <font color="blue">provide rebates</font> and predetermined <font color="blue">discounts</font>     <font color="blue">from list prices</font> and are <font color="blue">increasingly challenging</font> the <font color="blue">prices charged</font> for     <font color="blue">pharmaceutical</font>s  and  other  <font color="blue">medical products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">products may</font> not be     considered cost-<font color="blue">effective</font>, and <font color="blue">reimbursement</font> to the <font color="blue">patient may</font> not be     available  or  be  sufficient  to  allow the sale of our <font color="blue">products on</font> a     <font color="blue">competitive basis</font></td>
    </tr>
    <tr>
      <td>We, or our <font color="blue">collaborators</font> may not be able to negotiate     favorable <font color="blue">reimbursement</font> rates for our products</td>
    </tr>
    <tr>
      <td>If we, or our <font color="blue">collaborators</font>     fail  to obtain an <font color="blue">adequate level</font> of <font color="blue">reimbursement</font> for our products by     third-party payors, sales of the <font color="blue">drugs would</font> be <font color="blue">adversely affect</font>ed or there     may be no <font color="blue">commercially viable</font> market for the products</td>
    </tr>
    <tr>
      <td>The <font color="blue">drug research</font> and <font color="blue">development</font> industry has a history of patent and other     <font color="blue">intellectual</font>  property  <font color="blue">litigation</font>,  and  we may be involved in costly     <font color="blue"><font color="blue">intellectual</font> property</font> lawsuits</td>
    </tr>
    <tr>
      <td>The <font color="blue">drug research</font> and <font color="blue">development</font> industry has a history of patent and other     <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font>, and we believe these lawsuits are likely     to continue</td>
    </tr>
    <tr>
      <td>Legal <font color="blue">proceedings</font> relating to <font color="blue"><font color="blue">intellectual</font> property</font> would be     expensive, take <font color="blue">significant</font> time and divert <font color="blue">management</font>’s attention from     other business concerns</td>
    </tr>
    <tr>
      <td>Because we produce drug <font color="blue">candidates</font> for a broad     range of <font color="blue">therapeutic areas</font> and provide many different <font color="blue">cap<font color="blue">abilities</font></font> in this       21     ______________________________________________________________________         industry, we face potential patent <font color="blue">infringement</font> suits by companies that     <font color="blue">control patents</font> for similar drug <font color="blue">candidates</font> or <font color="blue">cap<font color="blue">abilities</font></font> or other suits     alleging <font color="blue">infringement</font> of their <font color="blue"><font color="blue">intellectual</font> property</font> rights</td>
    </tr>
    <tr>
      <td>There could be     <font color="blue">issued patents</font> of which we are not aware that our <font color="blue">products infringe</font> or     patents that we believe we do not infringe that we are <font color="blue">ultimately found</font> to     infringe</td>
    </tr>
    <tr>
      <td>Moreover, patent <font color="blue"><font color="blue">application</font>s</font> are in many cases maintained in     secrecy for <font color="blue">eighteen months</font> after filing or <font color="blue">even until patents</font> are issued</td>
    </tr>
    <tr>
      <td>The  <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature</font>     <font color="blue">frequently</font> occurs <font color="blue">substantially</font> later than the <font color="blue">date on which</font> the underlying     <font color="blue">discoveries</font> were made and patent <font color="blue"><font color="blue">application</font>s</font> were filed</td>
    </tr>
    <tr>
      <td>Because patent     <font color="blue"><font color="blue">application</font>s</font> can take many years to issue, there may be <font color="blue">currently pending</font>     <font color="blue"><font color="blue">application</font>s</font> of which we are unaware that may later result in <font color="blue">issued patents</font>     that we <font color="blue">infringe with</font> our products</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">technology</font> created under     our research and <font color="blue">development</font> <font color="blue">collaboration</font>s may infringe the <font color="blue">intellectual</font>     <font color="blue">property rights</font> of <font color="blue">third parties</font>, in which case we may not receive milestone     or royalty <font color="blue">revenue from</font> those <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>If we do not prevail in an <font color="blue">infringement</font> lawsuit brought against us, we might     have to pay substantial damages, including <font color="blue">triple damages</font>, and we could be     required to stop the <font color="blue">infringing activity</font> or obtain a license to use the     patented <font color="blue">technology</font> or redesign our products so as not to infringe the     patent</td>
    </tr>
    <tr>
      <td>We  may not be able to <font color="blue">enter <font color="blue">into licensing</font> arrangements at</font> a     <font color="blue">reasonable cost</font> or <font color="blue">effective</font>ly redesign our products</td>
    </tr>
    <tr>
      <td>Any <font color="blue">inability</font> to     <font color="blue">secure licenses</font> or <font color="blue">alternative</font> <font color="blue">technology</font> could delay the <font color="blue">introduction</font> of     our products or prevent us from <font color="blue">manufacturing</font> or <font color="blue">selling products</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">intellectual</font> property</font> rights we rely on to protect our <font color="blue"><font color="blue">proprietary</font> drug</font>     <font color="blue">candidates</font> and the <font color="blue">technology</font> underlying our tools and <font color="blue"><font color="blue">techniques</font> may</font> be     inadequate to prevent <font color="blue">third parties</font> from using our <font color="blue">technology</font> or developing     competing <font color="blue">cap<font color="blue">abilities</font></font> or to protect our interests in our <font color="blue"><font color="blue">proprietary</font> drug</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success will depend</font> in part on our ability to <font color="blue">protect patents</font> and     maintain the secrecy of <font color="blue">proprietary</font> processes and other <font color="blue">technologies</font> we     develop for the testing and synthesis of <font color="blue">chemical compounds</font> in the drug     <font color="blue">discovery</font> process</td>
    </tr>
    <tr>
      <td>In addition, one of our business strategies is to develop     our own <font color="blue"><font color="blue">proprietary</font> drug</font> <font color="blue">candidates</font> and enter into <font color="blue">collaboration</font>s with     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font> for the <font color="blue">development</font> of these drug     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>In  order  to  protect our rights to our <font color="blue"><font color="blue">proprietary</font> drug</font>     <font color="blue">candidates</font>, we must obtain and maintain the <font color="blue"><font color="blue">intellectual</font> property</font> rights to     such drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We currently have <font color="blue">eight issued</font> <font color="blue">United States </font>patents     and numerous patent <font color="blue"><font color="blue">application</font>s</font> on file with the <font color="blue">United States </font>Patent and     <font color="blue">Trademark Office </font>and around the world</td>
    </tr>
    <tr>
      <td>Any patents that we may own or license now or in the <font color="blue">future may</font> not afford     <font color="blue">meaningful protection</font> for our drug <font color="blue">candidates</font> or our <font color="blue">technology</font> and tools</td>
    </tr>
    <tr>
      <td>In order to protect or enforce our <font color="blue"><font color="blue">intellectual</font> property</font> rights, we may have     to initiate legal <font color="blue">proceedings</font> against <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our efforts to enforce     and maintain our <font color="blue"><font color="blue">intellectual</font> property</font> rights may not be successful and may     result in substantial costs and diversion of <font color="blue">management</font> time</td>
    </tr>
    <tr>
      <td>In addition,     other <font color="blue">companies may challenge</font> our patents and, as a result, these patents     could be narrowed, invalidated or rendered unenforceable, or we may be     forced to stop using the <font color="blue">technology</font> covered by these patents or to license     the <font color="blue">technology</font> from <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, current and <font color="blue">future patent</font>     <font color="blue"><font color="blue">application</font>s</font> on which we <font color="blue">depend may</font> not result in the issuance of patents in     the  <font color="blue">United States </font>or foreign countries</td>
    </tr>
    <tr>
      <td>Even if our rights are valid,     enforceable and broad in scope, <font color="blue">competitors</font> may develop drug <font color="blue">candidates</font> or     other <font color="blue">products based on</font> similar research or <font color="blue">technology</font> that is not covered     by our patents</td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font> relating to or <font color="blue">affecting</font> our business may have been     filed by a number of <font color="blue">pharmaceutical</font> and bio<font color="blue">pharmaceutical</font> companies and     <font color="blue">academic institutions</font></td>
    </tr>
    <tr>
      <td>A number of the <font color="blue">technologies</font> in these <font color="blue"><font color="blue">application</font>s</font> or     <font color="blue">patents may conflict with</font> our <font color="blue">technologies</font>, patents or patent <font color="blue"><font color="blue">application</font>s</font>,     <font color="blue">which could reduce</font> the scope of <font color="blue">patent protection</font> we <font color="blue">could otherwise</font> obtain</td>
    </tr>
    <tr>
      <td>We <font color="blue">could also become involved</font> in interference <font color="blue">proceedings</font> in <font color="blue"><font color="blue">connection</font> with</font>     one or more of our patents or patent <font color="blue"><font color="blue">application</font>s</font> to determine priority of     <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that we are the first creator of <font color="blue">inventions</font>     covered by pending patent <font color="blue"><font color="blue">application</font>s</font>, or that we were the first to file     patent <font color="blue"><font color="blue">application</font>s</font> for any such <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Drug <font color="blue">candidates</font> we develop that are approved for <font color="blue">commercial marketing by</font> the     FDA would be subject to the provisions of the <font color="blue">Drug Price Competition </font>and     <font color="blue">Patent Term Restoration Act </font>of 1984, known as the “Hatch-Waxman Act</td>
    </tr>
    <tr>
      <td>” The     Hatch-Waxman Act <font color="blue">provides companies with marketing exclusivity</font> for varying     time <font color="blue">periods during which generic versions</font> of a drug may not be marketed and     allows  companies  to apply to extend <font color="blue">patent protection</font> for up to five     <font color="blue">additional</font> years</td>
    </tr>
    <tr>
      <td>It <font color="blue">also provides</font> a means for <font color="blue">approving generic versions</font> of     a drug once the <font color="blue">marketing exclusivity period</font> has ended and all relevant     patents have expired</td>
    </tr>
    <tr>
      <td>The period of exclusive marketing, however, may be     shortened if a patent is <font color="blue">successfully</font> challenged and defeated, which could     reduce the amount of royalties we       22     ______________________________________________________________________         receive on the product</td>
    </tr>
    <tr>
      <td><font color="blue">Agreements </font>we have with our employees, <font color="blue">consultants</font> and <font color="blue">collaborators</font> may not     <font color="blue">afford adequate protection</font> for our <font color="blue">trade secret</font>s, <font color="blue">confidential</font> information     and other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">patent protection</font>, we <font color="blue">also rely on copyright</font> and trademark     protection, <font color="blue">trade secret</font>s, know-how, continuing <font color="blue">technological</font> innovation and     <font color="blue">licensing opportunities</font></td>
    </tr>
    <tr>
      <td>In an effort to maintain the <font color="blue"><font color="blue">confidential</font>ity</font> and     ownership of our <font color="blue">trade secret</font>s and <font color="blue">proprietary</font> information, we require our     employees,  <font color="blue">consultants</font>  and  advisors  to execute <font color="blue"><font color="blue">confidential</font>ity</font> and     <font color="blue">proprietary</font>  information <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue"><font color="blue">agreement</font>s</font> may not     provide us with adequate protection against improper use or <font color="blue">disclosure</font> of     <font color="blue">confidential</font> information and there may not be <font color="blue">adequate remedies</font> in the event     of <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may from time to time     <font color="blue">hire scientific personnel formerly employed by</font> other <font color="blue">companies involved</font> in     one or more areas similar to the <font color="blue">activities</font> we conduct</td>
    </tr>
    <tr>
      <td>In some situations,     our <font color="blue"><font color="blue">confidential</font>ity</font> and <font color="blue">proprietary</font> information <font color="blue"><font color="blue">agreement</font>s</font> may conflict     with, or be subject to, the rights of <font color="blue">third parties</font> with whom our employees,     <font color="blue">consultants</font> or advisors have <font color="blue">prior employment</font> or <font color="blue">consulting relationships</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  require  our  employees  and <font color="blue">consultants</font> to maintain the     <font color="blue"><font color="blue">confidential</font>ity</font> of all <font color="blue">proprietary</font> information of their <font color="blue">previous employers</font>,     these <font color="blue">individuals</font>, or we, may be subject to <font color="blue">allegations</font> of <font color="blue">trade secret</font>     <font color="blue">misappropriation</font>  or  other  similar claims as a result of their prior     <font color="blue">affiliations</font></td>
    </tr>
    <tr>
      <td>Finally, others may <font color="blue">in<font color="blue">dependent</font>ly</font> develop <font color="blue">substantially</font>     equivalent <font color="blue">proprietary</font> information and <font color="blue">techniques</font> or <font color="blue">otherwise gain access</font>     to our <font color="blue">trade secret</font>s</td>
    </tr>
    <tr>
      <td>Our failure or <font color="blue">inability</font> to protect our <font color="blue">proprietary</font>     information and <font color="blue"><font color="blue">techniques</font> may</font> inhibit or limit our ability to compete     <font color="blue">effective</font>ly, or <font color="blue">exclude certain <font color="blue">competitors</font> from</font> the market</td>
    </tr>
    <tr>
      <td>The <font color="blue">drug research</font> and <font color="blue">development</font> industry is <font color="blue">highly competitive</font>, and we     <font color="blue">compete with</font> some companies that offer a <font color="blue">broader range</font> of <font color="blue">cap<font color="blue">abilities</font></font> and     have <font color="blue">better access</font> to <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> <font color="blue">industries</font> are <font color="blue">characterized by rapid</font>     and continuous <font color="blue">technological</font> innovation</td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> companies worldwide     that are engaged in the research and <font color="blue">discovery</font>, licensing, <font color="blue">development</font> and     <font color="blue">commercialization</font> of drug <font color="blue">candidates</font>, including <font color="blue">Arena Pharmaceuticals Inc</font></td>
    </tr>
    <tr>
      <td>; <font color="blue">deCODE genetics</font>, Inc</td>
    </tr>
    <tr>
      <td>; <font color="blue">Exelixis Inc</font></td>
    </tr>
    <tr>
      <td>; Theravance, Inc</td>
    </tr>
    <tr>
      <td>; and <font color="blue">Vertex Pharmaceuticals Incorporated</font></td>
    </tr>
    <tr>
      <td>Some  of our <font color="blue">competitors</font> have a <font color="blue">broader range</font> of <font color="blue">cap<font color="blue">abilities</font></font> and have     greater access to financial, technical, scientific, <font color="blue">regulatory</font>, business     <font color="blue">development</font>, recruiting and other <font color="blue">resources than</font> we do</td>
    </tr>
    <tr>
      <td>Their access to     <font color="blue">greater resources may allow them</font> to develop processes or products that are     more <font color="blue">effective</font>, safer or <font color="blue">less costly</font>, or gain greater <font color="blue">market <font color="blue">acceptance</font></font>,     than products we develop or for which they obtain FDA approval more rapidly     than we do</td>
    </tr>
    <tr>
      <td>We anticipate that we <font color="blue">will face increased competition</font> in the     <font color="blue">future as new companies enter</font> the market and advanced <font color="blue">technologies</font> become     available</td>
    </tr>
    <tr>
      <td>We face <font color="blue">potential <font color="blue">liability</font></font> related to the privacy of health information we     obtain from <font color="blue"><font color="blue">research institution</font>s</font></td>
    </tr>
    <tr>
      <td>Most <font color="blue">health care</font> providers, including <font color="blue"><font color="blue">research institution</font>s</font> from whom we or     our  <font color="blue">collaborators</font>  obtain patient information, are subject to privacy     <font color="blue">regulations</font>  promulgated  under  the  <font color="blue">Health Insurance Portability </font>and     <font color="blue">Accountability Act </font>of 1996, <font color="blue">or HIPAA Although </font>we are not <font color="blue">directly regulated</font>     by HIPAA, we could face substantial <font color="blue">criminal penalties</font> if we knowingly     receive <font color="blue">individually identifiable health</font> information from a <font color="blue">health care</font>     provider or <font color="blue">research institution</font> that has not satisfied HIPPA’s <font color="blue">disclosure</font>     standards</td>
    </tr>
    <tr>
      <td>In addition, certain state <font color="blue">privacy laws</font> and <font color="blue">genetic testing laws</font>     <font color="blue">may apply directly</font> to our <font color="blue">operations</font> and/or those of our <font color="blue">collaborators</font> and     may impose <font color="blue">restrictions on</font> our use and <font color="blue">dissemination</font> of <font color="blue">individuals</font>’ health     information</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">patients about whom</font> we or our <font color="blue">collaborators</font> obtain     information, as well as the providers who share this information with us,     may have <font color="blue">contractual rights</font> that limit our ability to use and disclose the     information</td>
    </tr>
    <tr>
      <td>Claims that we have violated <font color="blue">individuals</font>’ privacy rights or     breached our contractual <font color="blue">obligations</font>, even if we are not found liable, could     be  expensive and time-consuming to defend and could result in adverse     publicity that <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________                               RISKS RELATED TO OUR STOCK       Our  officers and <font color="blue">directors</font> have <font color="blue">significant</font> control over us and their     <font color="blue"><font color="blue">interests may</font> differ from</font> those of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>At  June  30,  2006,  our <font color="blue">directors</font> and officers beneficially owned or     controlled approximately 13prca of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">Individually </font>and in the     aggregate,  these <font color="blue">stockholders</font> <font color="blue">significant</font>ly influence our <font color="blue">management</font>,     affairs and all matters requiring <font color="blue">stockholder approval</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">stockholders</font>     may vote their shares in a way with which other <font color="blue">stockholders</font> do not agree</td>
    </tr>
    <tr>
      <td>In  particular, this <font color="blue">concentration</font> of <font color="blue">ownership may</font> have the effect of     delaying,  <font color="blue">deferring</font> or preventing an <font color="blue">acquisition</font> of us or entrenching     <font color="blue">management</font> and may <font color="blue">adversely affect</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our quarterly operating results could fluctuate <font color="blue">significant</font>ly, which could     cause our stock price to decline</td>
    </tr>
    <tr>
      <td>Entering <font color="blue">into licensing</font> or <font color="blue">drug <font color="blue">discovery</font></font>     <font color="blue">collaboration</font>s typically involves <font color="blue">significant</font> technical evaluation and/or     <font color="blue">commitment</font> of <font color="blue">capital by</font> our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">negotiation</font> can be     lengthy  and  is  subject  to a number of <font color="blue">significant</font> risks, including     <font color="blue">collaborators</font>’ budgetary constraints and internal <font color="blue">acceptance</font> reviews</td>
    </tr>
    <tr>
      <td>In     addition, a <font color="blue">significant</font> portion of our revenue is <font color="blue">attributable</font> to up-front     payments  and <font color="blue">milestones</font> that are non-recurring</td>
    </tr>
    <tr>
      <td>Further, some of our     <font color="blue">collaborators</font> can influence when we deliver products and perform services,     and therefore receive revenue, under their <font color="blue">contracts with us</font></td>
    </tr>
    <tr>
      <td>Due to these     factors, our operating results could fluctuate <font color="blue">significant</font>ly from quarter to     quarter</td>
    </tr>
    <tr>
      <td>In  addition,  we may experience <font color="blue">significant</font> <font color="blue">fluctuations</font> in     quarterly  operating  results  due  to  factors  such  as  general and     industry-specific economic <font color="blue">conditions</font> that may affect the research and     <font color="blue">development</font> <font color="blue">expenditures</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font> companies</font></td>
    </tr>
    <tr>
      <td>Due to the <font color="blue">possibility</font> of <font color="blue">fluctuations</font> in our revenue and expenses, we     believe that quarter-to-quarter comparisons of our operating results are not     a good <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>Our operating results in some     quarters  may  not  meet the <font color="blue">expectations</font> of <font color="blue">stock market analysts</font> and     investors</td>
    </tr>
    <tr>
      <td>If we do not meet analysts’ and/or investors’ <font color="blue">expectations</font>, our     <font color="blue">stock price could</font> decline</td>
    </tr>
    <tr>
      <td>Because our <font color="blue">stock price may</font> be volatile, our <font color="blue">stock price could</font> experience     substantial declines</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">historically</font> experienced and may     continue to experience <font color="blue">volatility</font></td>
    </tr>
    <tr>
      <td>The high and low closing bids for our     <font color="blue">common stock</font> were dlra9dtta67 and dlra5dtta99 <font color="blue">respectively</font> in fiscal 2006, and dlra9dtta73 and     dlra5dtta66 <font color="blue">respectively</font> in fiscal 2005</td>
    </tr>
    <tr>
      <td>Our quarterly operating results, the     success  or failure of our internal <font color="blue">drug <font color="blue">discovery</font></font> efforts, changes in     general  <font color="blue">conditions</font>  in the economy or the <font color="blue">financial markets</font> and other     <font color="blue">development</font>s <font color="blue">affecting</font> our <font color="blue">collaborators</font>, our <font color="blue">competitors</font> or us could cause     the  <font color="blue">market price</font> of our <font color="blue">common stock</font> to fluctuate <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">volatility</font>  <font color="blue">coupled with market declines</font> in our <font color="blue">industry over</font> the past     <font color="blue">several years</font> have affected the <font color="blue">market price</font>s of <font color="blue">securities issued by</font> many     companies, often for <font color="blue">reasons unrelated</font> to their operating performance, and     may <font color="blue">adversely affect</font> the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In the past, securities     class action <font color="blue">litigation</font> has often been instituted following periods of     <font color="blue">volatility</font> in the <font color="blue">market price</font> of a company’s securities</td>
    </tr>
    <tr>
      <td>A securities class     <font color="blue">action suit against us could</font> result in potential li<font color="blue">abilities</font>, substantial     costs and the diversion of <font color="blue">management</font>’s attention and resources, regardless     of whether we win or lose</td>
    </tr>
    <tr>
      <td>Because we do not intend to pay dividends, <font color="blue">stockholders</font> will benefit from an     <font color="blue">investment</font> in our <font color="blue">common stock</font> only if it appreciates in value</td>
    </tr>
    <tr>
      <td>We have never declared or paid any <font color="blue"><font color="blue">cash dividends</font> on</font> our <font color="blue">common stock</font> and     are restricted in our ability to do so under our current credit <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently intend</font> to retain our <font color="blue">future earnings</font>, if any, to finance the     expansion of our business and do not expect to pay any <font color="blue">cash dividends</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>As a result, the success of an <font color="blue">investment</font> in our common     stock  will  <font color="blue">depend entirely upon</font> any <font color="blue">future appreciation</font></td>
    </tr>
    <tr>
      <td>There is no     guarantee that our <font color="blue">common stock</font> will appreciate in value or even maintain     the price at which <font color="blue">stockholders</font> have purchased their shares</td>
    </tr>
    <tr>
      <td>24     ______________________________________________________________________         The ability of our <font color="blue">stockholders</font> to control our policies and effect a change     of control of our company is limited, which may not be in the <font color="blue">best interests</font>     of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>There are provisions in our <font color="blue">certificate</font> of <font color="blue">incorporation</font> and bylaws that may     discourage a <font color="blue"><font color="blue">third party</font> from</font> making a proposal to acquire us, even if some     of  our  <font color="blue">stockholders</font>  might consider the proposal to be in their best     interests</td>
    </tr>
    <tr>
      <td>These include the <font color="blue">following provisions</font> in our <font color="blue">certificate</font> of     <font color="blue">incorporation</font>:       ·                  Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> provides for three     classes of <font color="blue">directors</font> with the term of office of one class <font color="blue">expiring each</font>     year,  commonly  referred  to  as  a  “<font color="blue">staggered board</font></td>
    </tr>
    <tr>
      <td>” By preventing     <font color="blue">stockholders</font> from voting on the election of more than one class of <font color="blue">directors</font>     at any <font color="blue">annual meeting</font> of <font color="blue">stockholders</font>, this <font color="blue">provision may</font> have the effect of     keeping the <font color="blue">current members</font> of our board of <font color="blue">directors</font> in control for a     <font color="blue">longer period</font> of time than <font color="blue">stockholders</font> may desire</td>
    </tr>
    <tr>
      <td>·                  Our <font color="blue">certificate</font> of <font color="blue">incorporation</font> authorizes our board of     <font color="blue">directors</font> to <font color="blue">issue shares</font> of <font color="blue">preferred stock</font> without <font color="blue">stockholder approval</font>     and to establish the <font color="blue">preferences</font> and rights of any <font color="blue">preferred stock</font> issued,     which  <font color="blue">would allow</font> the board to issue one or more classes or series of     <font color="blue">preferred stock</font> that <font color="blue">could discourage</font> or delay a <font color="blue">tender offer</font> or change in     control</td>
    </tr>
    <tr>
      <td>In addition, our board of <font color="blue">directors</font> approved a <font color="blue">Rights Agreement </font>on August 2,     2001, which could prevent or deter a <font color="blue">potential unsolicited takeover</font> of us by     causing  substantial  dilution  of  an  acquirer of 15prca or more of our     outstanding <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We are also subject to the business <font color="blue">combination</font>     provisions of Section 203 of the Delaware General Corporation Law, which, in     general, imposes restrictions upon acquirers of 15prca or more of our stock</td>
    </tr>
    <tr>
      <td>As     a result, it is <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire control of us without     the  approval  of  the  board of <font color="blue">directors</font> and, therefore, mergers and     <font color="blue"><font color="blue">acquisition</font>s</font>  of  us  that our <font color="blue">stockholders</font> may consider in their best     <font color="blue">interests may</font> not occur</td>
    </tr>
  </tbody>
</table>